Patents Assigned to Cell Therapeutics, Inc.
-
Patent number: 6075029Abstract: A new class of xanthine compounds, variously substituted at the 1, 3, 7 and 8 positions, is characterized by an ability to modulate the activity of key enzymes involved in drug metabolism. These compounds generally are useful in affecting drug metabolism and, particularly, in extending the circulating half-life of compounds that are metabolized via P-450-mediated pathways.Type: GrantFiled: January 2, 1998Date of Patent: June 13, 2000Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Anil M. Kumar, Paul Woodson
-
Patent number: 6060263Abstract: There is disclosed cDNA sequences and polypeptides having the enzyme lysophosphatidic acid acyltransferase (LPAAT) activity. LPAAT is also known as 1-acyl sn-glycerol-3-phosphate acyltransferase.Type: GrantFiled: September 21, 1999Date of Patent: May 9, 2000Assignee: Cell Therapeutics, Inc.Inventors: David W. Leung, James W. West, Christopher K. Tompkins
-
Patent number: 6057328Abstract: Disclosed are methods for treating conditions resulting from hyperoxia or mechanical ventilation comprising the administration of a compound of the formula: ##STR1## wherein R.sub.1 is a substantially pure resolved R enantiomer .omega.-1, secondary alcohol-substituted (C.sub.5-8) alkyl; and R.sub.2 and R.sub.3 are independently hydrogen atom or a (C.sub.1-12) alkyl optionally containing one or two oxygen atoms in place of non-adjacent carbon atoms.Type: GrantFiled: December 31, 1997Date of Patent: May 2, 2000Assignee: Cell Therapeutics, Inc.Inventors: Jack W. Singer, Edward Abraham
-
Patent number: 6043250Abstract: Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:CORE MOIETY --(R).sub.jwherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C(.sub.1-10) alkyl, C(.sub.2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C(.sub.1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.Type: GrantFiled: June 7, 1995Date of Patent: March 28, 2000Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Alistair J. Leigh, Gail E. Underiner, Anil M. Kumar, Glenn C. Rice
-
Patent number: 6020337Abstract: Therapeutic compounds, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, having a formula: ##STR1## wherein R.sub.0 is selected from the group consisting of hydrogen, halo, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, wherein the substituents of substituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl are other than halo; n is an integer from one to sixteen; R.sub.1, R.sub.2, and R.sub.3 are independently selected from the group consisting of a halo; haloacetoxy; hydrogen; hydroxy; oxo; --N.dbd.C.dbd.S; --N.dbd.C.dbd.O; --0--C.tbd.N; --C.tbd.N; --N.dbd.N.dbd.N; and --C--(R.sub.5).sub.3, R.sub.5 being independently a halo or hydrogen, at least one R.sub.5 being halo, at least one of R.sub.1, R.sub.2, and R.sub.3 being halo, cyano, isocyano, isothiocyano, azide or haloacetoxy group; R.sub.4 is hydrogen, C.sub.(1-6) alkyl, C.sub.(1-6) alkenyl, cyclo C.sub.Type: GrantFiled: September 16, 1997Date of Patent: February 1, 2000Assignee: Cell Therapeutics, Inc.Inventors: Alistair J. Leigh, John Michnick, Anil M. Kumar, J. Peter Klein, Gail Underiner
-
Patent number: 5985926Abstract: There is disclosed a method of preventing or delaying the occurrence of acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV) seropositive humans by administering an effective amount of a compound that inhibits cellular signaling through a specific phospholipid-based cellular signaling and signal amplification pathway. The invention further provides a method for preventing or delaying clinical symptoms of a group of viral diseases wherein the viral disease is mediated by host cell viral replication. The invention provides an advantage by attacking host cellular signaling mechanisms to prevent the development of drug resistance from rapidly mutating viruses.Type: GrantFiled: February 10, 1997Date of Patent: November 16, 1999Assignee: Cell Therapeutics, Inc.Inventors: David W. Leung, Gail E. Underiner, Jack W. Singer
-
Patent number: 5965564Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: March 20, 1998Date of Patent: October 12, 1999Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5955624Abstract: Alk-1-enyl glycerol derivatives and method of preparing same. The derivatives stimulate cell and tissue growth.Type: GrantFiled: June 7, 1995Date of Patent: September 21, 1999Assignee: Cell Therapeutics, Inc.Inventors: Edward Nudelman, Sen-Itiroh Hakomori
-
Patent number: 5952480Abstract: There is disclosed cDNA sequences and polypeptides having the enzyme CDP-diacylglycerol synthase (CDS) activity. CDS is also known as CTP:phosphatidate cytidylytransferase. There is further disclosed methods for isolation and production of polypeptides involved in phosphatidic acid metabolism and signaling in mammalian cells, in particular, the production of purified forms of CDS.Type: GrantFiled: June 28, 1996Date of Patent: September 14, 1999Assignee: Cell Therapeutics, Inc.Inventors: David W. Leung, Reitha Weeks
-
Patent number: 5929081Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease andType: GrantFiled: June 7, 1995Date of Patent: July 27, 1999Assignee: Cell Therapeutics Inc.Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer
-
Patent number: 5889011Abstract: Compounds and pharmaceutical compositions thereof comprise the formula:(R)j- (core moiety),including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, alkyl (C.sub.1-6) or alkenyl (C.sub.1-6), and at least one R has the formula I: ##STR1## wherein n is an integer from four to eighteen; each R'.sub.1 and R'.sub.2 is independently hydrogen, alkyl (C.sub.1-4) or alkenyl (C.sub.1-4), the alkyl or alkenyl groups being preferably substituted by a halogen, hydroxyl, ketone or dimethylamino group and/or may be interrupted by an oxygen or hydrogen atom or an alkyl (C.sub.1-4) group; and each R'.sub.3 and R'.sub.4 is independently hydrogen or methyl. Preferably, n is an integer from six to ten, R'.sub.1 and R'.sub.Type: GrantFiled: June 27, 1997Date of Patent: March 30, 1999Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Gail E. Underiner, Alistair J. Leigh
-
Patent number: 5866576Abstract: Disclosed are enantiomers, diastereomers, salts, solvates, hydrates and mixtures thereof, of formula I: ##STR1## The core moiety is a monocyclic ring structure having five to six ring atoms and two nitrogen atoms at the 1 and 3 positions, n is an integer from 4 to 16, R.sub.1 and R.sub.2 are hydrogen, halogen or C.sub.1-12 alkyl or alkenyl, and (CH.sub.2).sub.n may be optionally substituted by a hydroxyl, halogen, oxygen, a C.sub.1-4 alkyl group or a dimethylamino group. The compounds and pharmaceutical composition thereof are useful in methods for treating an individual having a disease or treatment-induced toxicity mediated through a second messenger.Type: GrantFiled: January 3, 1997Date of Patent: February 2, 1999Assignee: Cell Therapeutics, Inc.Inventors: Gail Underiner, J. Peter Klein, John Michnick, Alistair Leigh, Anil Kumar
-
Patent number: 5859018Abstract: There is disclosed a method for:(1) inhibiting new blood vessel formation that is useful for treating or preventing progression of diabetic retinopathy, cavernous haemangiomas, Kaposi's sarcoma, tumors composed of endothelial-like cells, and growth of cancer cells by preventing their development of a new blood supply:(2) suppressing development of kidney diseases due to cytokine induced proliferation of mesangial cells and/or glomerular epithelial cells that is useful for treating or preventing progression of diabetic glomerulosclerosis and other glomerulonephritides of various types and etiologies;(3) preventing joint destruction accompanying rheumatoid arthritis due to proliferation of synovial cells;(4) suppressing manifestations of psoriasis due to proliferation of keratinocytes and accumulation of inflammatory cells;(5) suppressing accelerated atherogenesis involved in restenosis of coronary vessels or other arterial vessels following angioplasty;(6) suppressing atherogenesis, coronary artery disease andType: GrantFiled: June 7, 1995Date of Patent: January 12, 1999Assignee: Cell Therapeutics, Inc.Inventors: Paul A. Brown, Stuart L. Bursten, Glenn C. Rice, Jack W. Singer
-
Patent number: 5859222Abstract: Disclosed are human cDNA and polypeptides sequences having phosphatidylcholine phospholipase D (PCPLD).Type: GrantFiled: December 17, 1996Date of Patent: January 12, 1999Assignee: Cell Therapeutics, Inc.Inventors: David W. Leung, Christopher K. Tompkins
-
Patent number: 5859017Abstract: In a method for treating or preventing allergy or allergic disorders an effective amount of a compound that inhibits intracellular generation of phosphatidic acid and diacylglycerol is administered. The intracellular generation of phosphatidic acid and diacylglycerol results from allergen presentation or mast cell/basophil activation.Type: GrantFiled: April 1, 1994Date of Patent: January 12, 1999Assignee: Cell Therapeutics, Inc.Inventors: Elisa Eiseman, Emer Clarke, Jack W. Singer, Stuart L. Bursten
-
Patent number: 5856331Abstract: There is disclosed a method for preventing tissue injury caused by tissue hypoxia and reoxygenation, comprising administering a compound that inhibits signal transduction by inhibiting cellular accumulation of linoleoyl phosphatidic acid (PA) through an inhibition of the enzyme LPAAT (lysophosphatidic acyltransferase).Type: GrantFiled: October 10, 1997Date of Patent: January 5, 1999Assignee: Cell Therapeutics, Inc.Inventors: Stuart L. Bursten, Jack W. Singer, Glenn C. Rice
-
Patent number: 5837703Abstract: Therapeutic compounds have the formula:(X)j-(core moiety),j being an integer from one to three, the core moiety comprising a core moiety, the core moiety being a heterocycle having one ring or two-fused rings, each ring having five or six ring atoms, A being a carbon atom of the core moiety and attached to a terminal carbon atom of (CH.sub.2).sub.m, and X has a structure and X being a racemic mixture, R or S enantiomer, solvate, hydrate, or salt of: ##STR1## *C is a chiral carbon atom, n is an integer from one to four (preferably from one to three), one or more carbon atoms of (CH.sub.2).sub.n may be substituted by a keto or hydroxy group, and m is an integer from one to fourteen. Independently, R.sub.1 and R.sub.2 may be a hydrogen, a straight or branched chain alkyl or alkenyl of up to twelve carbon atoms in length, or --(CH.sub.2).sub.w R.sub.5, w being an integer from two to fourteen and R.sub.5 being a mono-, di- or tri-substituted or unsubstituted aryl group, substituents on R.sub.Type: GrantFiled: November 12, 1993Date of Patent: November 17, 1998Assignee: Cell Therapeutics, Inc.Inventors: Anil M. Kumar, John Michnick, Gail E. Underiner, J. Peter Klein, Glenn C. Rice
-
Patent number: 5824677Abstract: Disclosed are compounds having a straight or branched aliphatic hydrocarbon structure of formula I: ##STR1## In formula I, n is an integer from one to four and m is an integer from four to twenty. Independently, R.sub.1 and R.sub.2 are hydrogen, a straight or branched chain alkyl, alkenyl or alkynyl of up to twenty carbon atoms in length or --(CH.sub.2).sub.w R.sub.5. If R.sub.1 or R.sub.2 is --(CH.sub.2).sub.w R.sub.5, w may be an integer from one to twenty and R.sub.5 may be an hydroxyl, halo, C.sub.1-8 alkoxyl group or a substituted or unsubstituted carbocycle or heterocycle. Alternatively, R.sub.1 and R.sub.2 may jointly form a substituted or unsubstituted, saturated or unsaturated heterocycle having from four to eight carbon atoms, N being a hetero atom of the resulting heterocyle. R.sub.3 may be either hydrogen or C.sub.13. In the compounds, a total sum of carbon atoms comprising R.sub.1 or R.sub.2, (CH.sub.2).sub.n and (CH.sub.2).sub.m does not exceed forty. R.sub.Type: GrantFiled: June 7, 1995Date of Patent: October 20, 1998Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Gail E. Underiner, Anil M. Kumar
-
Patent number: 5817662Abstract: Compounds and pharmaceutical compositions thereof comprise the formula:(R)j-(core moiety),including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, wherein J is an integer from one to three, the core moiety is non-cyclic or comprises at least one, five- to seven-membered ring structure, R may be selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, alkyl (C.sub.1-6) or alkenyl (C.sub.1-6), and at least one R has the formula I: ##STR1## wherein n is an integer from four to eighteen; each R'.sub.1 and R'.sub.2 is independently hydrogen, alkyl (C.sub.1-4) or alkenyl (C.sub.1-4), the alkyl or alkenyl groups being preferably substituted by a halogen, hydroxyl, ketone or dimethylamino group and/or may be interrupted by an oxygen or hydrogen atom or an alkyl (C.sub.1-4) group; and each R'.sub.3 and R'.sub.4 is independently hydrogen or methyl. Preferably, n is an integer from six to ten, R'.sub.1 and R'.sub.Type: GrantFiled: June 6, 1995Date of Patent: October 6, 1998Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Gail E. Underiner, Alistair J. Leigh
-
Patent number: 5807861Abstract: A method for treating a disease caused by an undesirable cell response mediated by a proliferative intracellular signaling pathway is provided wherein an effective amount of a compound is administered. The compound, resolved enantiomers, diastereomers, hydrates, salts, solvates and mixtures thereof, has the formulaCORE MOIETY--(R).sub.jwherein j is an integer from one to three; the core moiety is xanthinyl; and R is independently selected from the group consisting of amine, hydrogen, halogen, hydroxyl, C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, 2-bromopropyl, 4-chloropentyl, cyclohexyl, cyclopentyl, 3-dimethylaminobutyl, 2-hydroxyethyl, 5-hydroxyhexyl, 3-hydroxy-n-butyl, 3-hydroxypropyl, 2-methoxyethyl, 4-methoxy-n-butyl, phenyl, and formula I, at least one R comprising formula I ##STR1## wherein (CH.sub.2).sub.n is optionally substituted; n is an integer from five to twenty; each R.sub.1 or R.sub.2 is independently hydrogen or an optionally substituted group that is herein defined; andwherein, when the (CH.Type: GrantFiled: June 7, 1995Date of Patent: September 15, 1998Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Gail E. Underiner, Anil M. Kumar, Lance H. Ridgers, Glenn C. Rice, David W. Leung